Aclarion (ACON) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Apr, 2026Executive summary
The annual meeting is scheduled for June 4, 2026, with voting on director elections, auditor ratification, and an amendment to the equity incentive plan.
Only stockholders of record as of April 10, 2026, are eligible to vote, with multiple voting methods available including online, mail, and in-person.
The board recommends voting in favor of all proposals, including the election of seven directors, auditor ratification, and the equity plan amendment.
Voting matters and shareholder proposals
Proposal 1: Elect seven director nominees to serve until the 2027 annual meeting.
Proposal 2: Ratify Haynie & Company as independent registered public accounting firm for fiscal year ending December 31, 2026.
Proposal 3: Approve an amendment to the 2022 Equity Incentive Plan, increasing the share reserve and annual grant limits.
Shareholders may submit proposals for the 2027 meeting by December 16, 2026, following SEC and bylaw requirements.
Board of directors and corporate governance
The board consists of seven members, with four deemed independent under Nasdaq and SEC rules.
Three standing committees: audit, compensation, and nominating/corporate governance, each with independent chairs.
The board values diversity and considers a broad range of qualifications for director nominees.
The board met nine times in 2025, with all directors attending at least 75% of meetings.
A written Code of Business Conduct and Ethics applies to all directors, officers, and employees.
Latest events from Aclarion
- Revenue up 65.6% to $75.7K; net loss $7.2M; $22.6M raised in 2025, $10.4M in 2026.ACON
Q4 202518 Mar 2026 - Non-invasive spinal diagnostics see clinical, commercial, and reimbursement momentum in key markets.ACON
Investor Update23 Jan 2026 - Non-invasive lumbar disc diagnostics show strong outcomes and payer traction, driving expansion.ACON
Investor Update12 Jan 2026 - Shelf registration enables up to $50M in offerings for AI-driven spine diagnostics in a high-need market.ACON
Registration Filing16 Dec 2025 - Healthcare tech firm targets $50M raise amid Nasdaq risks, leveraging patented MRS diagnostics.ACON
Registration Filing16 Dec 2025 - AI-driven diagnostics firm faces Nasdaq risks, offers 27.5M shares for resale, no direct proceeds.ACON
Registration Filing16 Dec 2025 - Up to $150M in securities to fund AI-driven diagnostics for back and neck pain; high risk, high potential.ACON
Registration Filing16 Dec 2025 - Key votes include director elections, auditor ratification, a reverse split, and equity plan changes.ACON
Proxy Filing2 Dec 2025 - Key votes include director elections, auditor ratification, share issuances, and a reverse stock split.ACON
Proxy Filing2 Dec 2025